Sangamo Therapeutics shares are trading higher after the company announced the FDA approved an accelerated pathway for ST-920 in Fabry disease. A BLA submission is expected in 2025.
Portfolio Pulse from Benzinga Newsdesk
Sangamo Therapeutics' shares rise as the FDA approves an accelerated pathway for their ST-920 treatment for Fabry disease, with a BLA submission expected in 2025.
October 22, 2024 | 1:43 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sangamo Therapeutics' stock is trading higher following the FDA's approval of an accelerated pathway for their ST-920 treatment for Fabry disease. This regulatory milestone is a positive development, with a BLA submission planned for 2025.
The FDA's approval of an accelerated pathway is a significant regulatory milestone for Sangamo Therapeutics, likely boosting investor confidence and driving the stock price higher. The anticipation of a BLA submission in 2025 further supports a positive outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100